25-01-2012 01:43 Parkinson's Disease: New Non-Surgical treatment. Parkinson's symptoms of Gait and Balance stay improved at 9 months with a TMJ mouth piece .
Here is the original post:
Parkinson's Disease: Balance, Gait (Walk) and Tremors Improve with New Non-Surgical Treatment Part 2 - Video
News Release
UB's Feng says the use of iPSCs was "a game-changer for Parkinson's disease. It finally allowed us to obtain the material we needed to study this disease."
Download JPEG
Release Date: February 7, 2012
Summary:
-- UB researchers have discovered how mutations in parkin disrupt proper function of dopamine, the neurotransmitter that controls body movement.
-- They found that parkin mutations disrupt the precise actions of dopamine and produce more free radicals, which in turn destroy the dopamine neurons, leading to Parkinson's disease.
-- This is the first study to use live human neurons to investigate what role parkin plays in Parkinson's disease; this dramatic advance was made possible by the use of induced pluripotent stem cells.
-- Funding was provided by the Michael J. Fox Foundation for Parkinson's Research; the National Institutes of Health; SUNY REACH, a research network of SUNY academic medical centers; and NYSTEM, New York State's stem cell initiative.
BUFFALO, N.Y. -- Parkinson's disease researchers at the University at Buffalo have discovered how mutations in the parkin gene cause the disease, which afflicts at least 500,000 Americans and for which there is no cure.
The results are published in the current issue of Nature Communications.
The UB findings reveal potential new drug targets for the disease as well as a screening platform for discovering new treatments that might mimic the protective functions of parkin. UB has applied for patent protection on the screening platform.
"This is the first time that human dopamine neurons have ever been generated from Parkinson's disease patients with parkin mutations," says Jian Feng, PhD, professor of physiology and biophysics in the UB School of Medicine and Biomedical Sciences and the study's lead author.
As the first study of human neurons affected by parkin, the UB research overcomes a major roadblock in research on Parkinson's disease and on neurological diseases in general.
The problem has been that human neurons live in a complex network in the brain and thus are off-limits to invasive studies, Feng explains.
"Before this, we didn't even think about being able to study the disease in human neurons," he says. "The brain is so fully integrated. It's impossible to obtain live human neurons to study."
But studying human neurons is critical in Parkinson's disease, Feng explains, because animal models that lack the parkin gene do not develop the disease; thus, human neurons are thought to have "unique vulnerabilities."
"Our large brains may use more dopamine to support the neural computation needed for bipedal movement, compared to quadrupedal movement of almost all other animals," he says.
Since in 2007, when Japanese researchers announced they had converted human cells to induced pluripotent stem cells (iPSCs) that could then be converted to nearly any cells in the body, mimicking embryonic stem cells, Feng and his UB colleagues saw their enormous potential. They have been working on it ever since.
"This new technology was a game-changer for Parkinson's disease and for other neurological diseases," says Feng. "It finally allowed us to obtain the material we needed to study this disease."
The current paper is the fruition of the UB team's ability to "reverse engineer" human neurons from human skin cells taken from four subjects: two with a rare type of Parkinson's disease in which the parkin mutation is the cause of their disease and two healthy subjects who served as controls.
"Once parkin is mutated, it can no longer precisely control the action of dopamine, which supports the neural computation required for our movement," says Feng.
The UB team also found that parkin mutations prevent it from tightly controlling the production of monoamine oxidase (MAO), which catalyzes dopamine oxidation.
"Normally, parkin makes sure that MAO, which can be toxic, is expressed at a very low level so that dopamine oxidation is under control," Feng explains. "But we found that when parkin is mutated, that regulation is gone, so MAO is expressed at a much higher level. The nerve cells from our Parkinson's patients had much higher levels of MAO expression than those from our controls. We suggest in our study that it might be possible to design a new class of drugs that would dial down the expression level of MAO."
He notes that one of the drugs currently used to treat Parkinson's disease inhibits the enzymatic activity of MAO and has been shown in clinical trials to slow down the progression of the disease.
Parkinson's disease is caused by the death of dopamine neurons. In the vast majority of cases, the reason for this is unknown, Feng explains. But in 10 percent of Parkinson's cases, the disease is caused by mutations of genes, such as parkin: the subjects with Parkinson's in the UB study had this rare form of the disease.
"We found that a key reason for the death of dopamine neurons is oxidative stress due to the overproduction of MAO," explains Feng. "But before the death of the neurons, the precise action of dopamine in supporting neural computation is disrupted by parkin mutations. This paper provides the first clues about what the parkin gene is doing in healthy controls and what it fails to achieve in Parkinson's patients."
He noted in this study that these defects are reversed by delivering the normal parkin gene into the patients' neurons, thus offering hope that these neurons may be used as a screening platform for discovering new drug candidates that could mimic the protective functions of parkin and potentially even lead to a cure for Parkinson's.
While the parkin mutations are only responsible for a small percentage of Parkinson's cases, Feng notes that understanding how parkin works is relevant to all Parkinson's patients. His ongoing research on sporadic Parkinson's disease, in which the cause is unknown, also points to the same direction.
In addition to Feng, co-authors are Houbo Jiang, PhD, Yong Ren, PhD, Eunice Y. Yuen, all research assistant professors at UB; Ping Zhong, PhD, research scientist, Mahboobe Ghaedi, PhD, postdoctoral associate, Zhixing Hu, PhD, postdoctoral associate, and Zhen Yan, PhD, professor, all of the UB Department of Physiology and Biophysics. Other co-authors are Gissou Azabdaftari, MD, of the Roswell Park Cancer Institute, and Kazuhiro Nakaso, MD, of Tottori University in Japan.
The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York. UB's more than 28,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. Founded in 1846, the University at Buffalo is a member of the Association of American Universities.
See the original post here:
Parkinson's Disease: Study of Live Human Neurons Reveals the Disease's Genetic Origins, New Drug Targets
A six-month program of Tai Chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.
A study released this week in the New England Journal of Medicine compared a six-month tailored Tai Chi program to resistance training and stretching to see which was most effective at improving functional movement, walking and balance for Parkinson's patients.
Researchers randomly assigned 195 men and women ages 40 to 85 who were in stages one to four of Parkinson's disease (on a scale of one to five). Parkinson's is a neurological disorder caused by a loss of neurons that produce dopamine, a chemical involved with muscle function and movement coordination. That can result in tremors, stiffness, poor coordination and more difficulty doing daily activities. It can also lead to a higher risk of falls, which can cause serious injuries.
Tai Chi, a discipline that incorporates slow, deliberate movements, plus breathing, has health benefits that include reducing stress and improving balance and posture.
The study participants were randomly assigned to hourlong, twice weekly sessions of Tai Chi, resistance training or stretching for six months. Researchers assessed their status at the beginning of the study, at three and six months, and three months after the study ended.
The Tai Chi group did better than the stretching group on a few measures: leaning without losing balance, having better directional control of their body, and walking skills. They outperformed the resistance training group on balance and stride length. Those in the Tai Chi group also reduced their frequency of falls more than the stretching group, and on a par with the resistance group.
Three months after the study ended, those in the Tai Chi group were able to maintain the benefits they had gained.
"Since many training features in the program are functionally oriented," said Oregon Research Institute scientist Fuzhong Li in a news release, "the improvements in the balance and gait measures that we demonstrated highlight the potential of Tai Chi-based movements in rehabilitating patients with these types of problems and, consequently, easing cardinal symptoms of Parkinson's disease and improving mobility, flexibility, balance and range of motion." Li was the lead author of the study.
He added that Tai Chi has several advantages: "It is a low-cost activity that does not require equipment, it can be done anywhere, at any time, and the movements can be easily learned. It can also be incorporated into a rehabilitation setting as part of existing treatment. Similarly, because of its simplicity, certain aspects of this Tai Chi program can also be prescribed to patients as a self-care/home activity."
See the original post here:
Tai Chi may help Parkinson's patients regain balance
POSTED: 4:31 pm MST February 14, 2012
UPDATED: 4:59 pm MST February 14, 2012
LOS ANGELES -- More than one million Americans are living with Parkinson's disease. Right now, doctors diagnose it by conducting a physical exam that?s often unreliable, but that?s about to change.William used to be a professional welterweight fighter. Today, he?s fighting a different yet powerful opponent, Parkinson?s disease."I got Parkinson?s, Parkinson?s ain?t got me," William "Tank" Hill, a former boxer said. Debora Bergstrom is also battling the condition that causes tremors, balance problems and speech issues. The mom of three was diagnosed four years ago by a neurologist."She told me to stand up, walk, she rotated my arms and hands, and she said, yes, you have Parkinson's," Debora Bergstrom said.Many people wait years before getting that diagnosis. Doctors physically examine patients for the telltale symptoms to formulate their conclusion, but their observations aren?t always accurate.Forty percent of Parkinson?s patients are undiagnosed and at least 10 percent who are diagnosed don?t really have it. Doctor Louise Thomson says a new imaging test called DATscan is giving doctors a glimpse inside the Parkinson?s brain. First, doctors inject patients with a tracer. Then they scan the brain for dopamine, a chemical that Parkinson?s patients lack.Thomson says the test can tell doctors if the patient has Parkinson?s or just a tremor disorder, which is treated differently"This is a game changer. It?s going to lead to earlier diagnosis and clearer diagnosis for patients with tremors," Doctor Louise Thomson, MBChB, from Cedars-Sinai Medical Center explained.An earlier diagnosis means patients can start treatments sooner, potentially slowing symptom development of this devastating disease. For William and Debora, every symptom-free day matters. Now , doctors are one step closer to figuring that out. The following are comments from our users. Opinions expressed are neither created nor endorsed by TheDenverChannel.com. By posting a comment you agree to accept our Terms of Use. Comments are moderated by the community. To report an offensive or otherwise inappropriate comment, click the "Flag" link that appears beneath that comment. Comments that are flagged by a set number of users will be automatically removed.
See the article here:
Medical Breakthrough: First Test To Show Parkinson's Disease
CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- In an effort to study the interactions between genomics and Parkinson's disease, Cleveland Clinic has joined the ongoing efforts of 23andMe, a leading personal genetics company, to recruit Parkinson's patients to participate in research by contributing their DNA to a research database and completing online surveys about their health.
Currently, little is known about how genes relate to Parkinson's disease, the effectiveness of treatments, or the natural course of the disease. The goal of this collaborative research effort – which also has support from the Michael J. Fox Foundation, the National Parkinson Foundation and the Parkinson's Institute – is to discover how genes and the environment influence Parkinson's disease.
"We are aware of the limitations of today's treatments, so we are always thinking about what we can do to advance the care of this incurable disease," said Andre Machado, M.D., Ph.D., Director of Cleveland Clinic's Center for Neurological Restoration. "This collaboration will help us to learn more about the genomics of Parkinson's disease and how it may impact individualized care in the future."
The project is part of Cleveland Clinic's personalized healthcare initiative, which aims to drive discoveries that allow medical professionals to better predict risk for disease and response to therapies, with the ultimate goal to improve patient care.
"We are offering this opportunity to our patients because as part of our 'Patients First' mission, we feel it is an important collaboration that could lead to improvements in our ability to predict and treat Parkinson's disease," said Kathryn Teng, M.D., Director of the Center for Personalized Healthcare at Cleveland Clinic. "Donating saliva, blood or tissue for research is a form of 'Patient Philanthropy.' It empowers our patients to participate in medical research and discoveries that can improve healthcare for themselves and others."
Patients who volunteer for the study will be asked to provide a saliva sample for DNA analysis and agree to participate in online surveys about their experience with Parkinson's. 23andMe hopes to enroll 10,000 participants total; Cleveland Clinic expects to enroll about 1,000 patients toward this goal.
"The quality of the research will depend heavily on sample size. Patient enrollment and participation is critical to the success of the project," said Ryan Walsh, M.D., Ph.D., Director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas.
Patients who take part in the study will be enrolled in 23andMe's Parkinson's Disease Research Community, which will allow them to engage online with other Parkinson's patients and provides full access to 23andMe's Personal Genome Service.
23andMe first assembled its Parkinson's disease research initiative in June 2009. Within an 18-month period, 23andMe assembled and analyzed genetic data from more than 3,400 Parkinson's patients and successfully replicated the top 20 previously known genetic associations with Parkinson's disease in addition to determining new genetic associations for Parkinson's. Those findings were published in PLOS Genetics in June 2011. That study identified two novel loci, rs6812193 near SCARB2 and rs11868035 near SREBF1/RA11 and replicated those loci in an independent data cohort from the National Institute of Neurological Disease and Stroke (NINDS) database.
"We are very excited to be partnering with Cleveland Clinic and Dr. Machado. Integrating their clinical care with our online research model creates the opportunity for a new paradigm of medical research, that will ultimately benefit individuals with Parkinson's Disease," said Anne Wojcicki, CEO of 23andMe. "Participants enrolled through the Cleveland Clinic will join the more than 6,500 individuals with Parkinson's disease already in our research community – the largest cohort of Parkinson's patients in the world."
Participation is free and voluntary. Those who take part in the study will be identified by a unique code, not by their names, in order to protect their privacy. Participants can choose to receive a report summarizing the genes identified in their DNA, though these findings will not be placed in their medical record.
"Patients volunteering for the study are unlikely to benefit directly, but they can have a sizable role in improving care for future patients. That's what this partnership is all about for us," said Hubert Fernandez, M.D., Section Head, Movement Disorders at Cleveland Clinic's Center for Neurological Restoration.
To facilitate participation in the registry, Cleveland Clinic has detailed information and dedicated computer portals set up at locations where Parkinson's patients are most likely to be visiting, including main campus in Cleveland and the Lou Ruvo Center for Brain Health in Las Vegas. Two additional locations, Cleveland Clinic's Lakewood Hospital (Lakewood, Ohio) and Cleveland Clinic Florida (Weston, Fla.), will be enrolling patients as well. Patients can also email Cleveland Clinic at parkinsons@ccf.org or 23andMe at pd-help@23andme.com for more details or to sign up.
For more information about the research study, visit https://www.23andme.com/pd/.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, eight community hospitals and 18 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 167,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at http://www.clevelandclinic.org/. Follow us at http://www.twitter.com/ClevelandClinic.
About 23andMe
23andMe, Inc. is a leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service® enables individuals to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at http://www.23andme.com.
See the rest here:
Cleveland Clinic Joins 23andMe in the Search for Genetic Clues to Parkinson's Disease
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cleveland Clinic today said that it will recruit Parkinson's disease patients for 23andMe and the consumer genetics firm's ongoing research efforts in that area.
The patients will be recruited to contribute their DNA to 23andMe's research database and complete online surveys regarding their health. Participants will be enrolled in 23andMe's Parkinson's Disease Research Community, enabling them to engage with other Parkinson's patients while getting full access to 23andMe's Personal Genome Service.
Cleveland Clinic said the project is part of its own personalized healthcare initiative, which seeks to better predict risk for disease and response to therapies.
"We are offering this opportunity to our patients because as part of our 'Patients First' mission, we feel it is an important collaboration that could lead to improvements in our ability to predict and treat Parkinson's disease," Kathryn Teng, director of the Center for Personalized Healthcare at Cleveland Clinic, said in a statement.
23andMe began a research collaboration in March 2009 with the Michael J. Fox Foundation for Parkinson's Research, and the Parkinson's Institute and Clinical Center aimed at enrolling 10,000 people to be part of its Parkinson's Disease Research Community.
That collaboration led to a study published last year in PLoS Genetics that identified two new loci contributing to Parkinson's disease risk. The genome-wide association study involved 3,426 individuals with Parkinson's disease enrolled over an 18-month period.
23andMe CEO Anne Wojcicki said that the firm already has more than 6,500 individuals with Parkinson's disease in its research community, which she said is the largest cohort of Parkinson's disease patients in the world. Cleveland Clinic said that it expects to add about 1,000 patients to the program.
The rest is here:
Cleveland Clinic to Recruit Parkinson's Patients for 23andMe
16-08-2011 08:53 Researchers have discovered a new gene mutation they say causes Parkinson's disease. The mutation was identified in a large Swiss family with Parkinson's disease, using advanced DNA sequencing technology. The study, published in the American Journal of Human Genetics, was led by neuroscientists at the Mayo Clinic campus in Florida and included collaborators from the US, Canada, Europe, United Kingdom, Asia and the Middle East. "This finding provides an exciting new direction for Parkinson's disease research," says co-author Zbigniew Wszolek, MD, a Mayo Clinic neuroscientist. "Every new gene we discover for Parkinson's disease opens up new ways to understand this complex disease, as well as potential ways of clinically managing it." The team found that mutations in VPS35, a protein responsible for recycling other proteins within cells, caused Parkinson's disease in the Swiss family. Mutated VPS35 may impair the ability of a cell to recycle proteins as needed, which could lead to the kind of errant buildup of protein seen in some Parkinson's disease brains and in other diseases like Alzheimer's disease says co-author Owen Ross, Ph.D., a neuroscientist at Mayo Clinic in Florida. "In fact, expression of this gene has been shown to be reduced in Alzheimer's disease, and faulty recycling of proteins within cells has been linked to other neurodegenerative diseases," he says. In this video, Dr. Wszolek and Dr. Ross discuss Parkinson's disease and the study.
View post:
Mayo researchers: Genetic mutation linked to Parkinson's disease - Video
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/6e1829/global_parkinsons) has announced the addition of the "Global Parkinson's Disease Drug Pipeline Capsule - 2012" report to their offering.
Fore Pharma's latest report Global Parkinson's Disease Drug Pipeline Capsule - 2012 is an outline of all the key research and development (R&D) activities of the global parkinson's disease drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.
This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.
The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the parkinson's disease drug market is thoroughly covered by company and licensee with the deal summary.
Key Topics Covered:
1. Parkinson's Disease: Disease Definition
2. Parkinson's Disease Drug Pipeline Overview
3. Parkinson's Disease Phase 3 Clinical Trial Drug Pipeline Insights
4. Parkinson's Disease Phase 2 Clinical Trial Drug Pipeline Insights
5. Parkinson's Disease Phase 1 Clinical Trial Drug Pipeline Insights
6. Parkinson's Disease Preclinical Research Drug Pipeline Insights
7. Parkinson's Disease Drug Discovery Pipeline Insights
8. Geographic Landscape of Parkinson's Disease R&D Activities
8.1 Parkinson's Disease R&D Activities in North America
8.2 Parkinson's Disease R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Parkinson's Disease Drug Market
10 Research Methodology
For more information visit http://www.researchandmarkets.com/research/6e1829/global_parkinsons
Read the original:
Research and Markets: Global Parkinson's Disease Drug Pipeline Capsule - 2012
FAIRHOPE, Alabama -- Susie Glickman is an amazing line dancer.
It’s not because she can execute the Cupid Shuffle or the Electric Slide better than most.
Rather, it is because every step takes extra effort now that this 67-year-old Fairhope woman has Parkinson’s disease.
“I have it on my left side,” said Glickman, who was diagnosed with the chronic, progressive movement disorder in 2007. “I went in to see my doctor because my left arm didn’t feel like it was part of my body. When I found out it was Parkinson’s, I was shocked. I wanted to find out as much as I could about the disease.”
At first glance, Glickman’s condition isn’t obvious.
While moving a little slower these days, Glickman is fairly nimble. But this spunky grandmother struggles with tremors, weakness and balance issues.
Turning pages can be tiresome — or downright impossible. Often, she succumbs to exhaustion.
Nevertheless, Glickman considers herself lucky.
“The mid 60s is the prime age to get Parkinson’s,” she said. “It usually progresses slowly when you are diagnosed in your 60s. But the younger you have it, the faster it progresses.”
Glickman manages to move steadily while leading line-dancing classes in Mobile and Baldwin counties. The Los Angeles native also moonlights as a part-time joke writer for longtime employer and close friend Dolly Parton.
“I used to be Dolly’s personal secretary,” she proclaimed, her eyes dancing with delight. “Now I write the jokes she uses at her appearances.”
Today, Glickman has combined her dancing and writing talents to pursue her latest passion: educating others about Parkinson’s.
Glickman recently wrote, produced, choreographed and starred in “Dancing Feet Help Defeat Parkinson’s,” a 4-minute, 9-second video featuring 175 dancers at the James P. Nix Adult Activity Center in Fairhope doing the “Parkinson’s Disease Stomp Line Dance.”
She entered the short film in the American Academy of Neurology Foundation’s third annual Film Festival competition to raise awareness about why more research is needed to cure brain diseases, such as Alzheimer’s disease, stroke, autism, Parkinson’s disease and multiple sclerosis.
Judges will select the first- and second-place winners and the third-place winner will be chosen by popular vote. Nearly 300 films have been submitted since the festival began in 2010 and Glickman’s video is among 104 in this year’s contest.
Voting opened last week and people can view and vote for their favorite video through March 8 at http://www.NeuroFilmFestival.com.
The winner of the “Fan Favorite” award will receive a certificate and recognition at the 2012 Neuro Film Festival on April 22 in New Orleans. The festival will be held in conjunction with the foundation’s 64th annual meeting, the world’s largest meeting of neurologists with 10,000 attendees.
“My goal is to get as many people aware of this as possible and then get them to vote,” Glickman said. “We have a really good chance of winning because of the video’s originality.”
In the film, a room packed with men and women wearing bright red T-shirts and white pants follow Glickman in a dance set to the tune “Jingle Bells.”
As the video begins, participants shuffle their feet and wave their arms in unison, following Glickman’s lead. Before the song plays, Glickman’s voice can be heard reciting “The Parkinson’s Plea,” a poem she penned.
Then the music begins: “Parkinson’s, Parkinson’s, it’s a brain disease. Parkinson’s, Parkinson’s brings us to our knees. Parkinson’s, Parkinson’s makes our bodies freeze. Parkinson’s, Parkinson’s, help us cure it please ...”
Nearly 1 million people in the U.S. are living with Parkinson’s disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms. The primary motor signs of Parkinson’s disease include the following.
Tremor of the hands, arms, legs, jaw and face. Bradykinesia, or slowness of movement. Rigidity or stiffness of the limbs and trunk. Postural instability or impaired balance and coordination.
Glickman is hopeful her film will place in the top three. But, she says, “I think the video already is a winner.”
She asked Parkinson’s patients, their families and caregivers as well as friends from church and her line-dancing students in Fairhope and Mobile to appear in the video.
“I solicited everyone in town,” she said.
When the day of filming arrived, Glickman was overwhelmed.
“We had 175 people in the room and I didn’t know they would come until they showed up — and the mood was captured perfectly,” she said. “Most of the people didn’t line dance, but it turned out to be amazing.”
Glickman has been working for Parton since the 1970s, convincing the entertainer to hire her after showing up consistently at several of Parton’s California appearances, offering her lyric writing services.
“I told everyone I would be working for Dolly Parton one day,” Glickman said. “Eventually, Dolly said, ‘Give that squirrelly fan a job.’”
Glickman moved to Fairhope in the 1980s after working with Baldwin County native and author Fannie Flagg on Parton’s television show.
“I got sand in my shoes and that was it,” she said.
Parkinson’s may have slowed Glickman’s gait. But neither age, nor a progressive neurological disease can erode Glickman’s determination.
The same tenacity that landed her a job with Parton years ago is evident in her recent project.
“I truly believe that if you put your mind to something, you can get it done,” said Glickman, flashing a smile. “This film was a dream of mine.”
By LESLEY FARREY PACEY, Correspondent
See the original post:
Fairhope Parkinson's patient enters film in contest to awareness of disease
12-09-2011 16:02 Taylor French before and after treatments of Medical Cannabis for Parkinson's Disease. Please help us to save Taylor's life and make him healthy again. Any help on your part will aid him and provide hope for others who are afflicted with this terrible disease. Make checks payable to Health Village Seminars (Bank of America) and email frenchtaylor@gmail.com so we can keep track. Send donations and ship items to: Health Village Seminars, c/o Taylor French 2936 Calle Frontera, San Clemente, CA 92673 Phone 949-842-9291 Thanks so much in advance for your help, Mike Paulus (long time friend), Janet (caregiver)
Continued here:
Taylor French on Medical Cannabis for Parkinson's Disease - Video
04-09-2011 09:59 Information About Parkinson's Disease From A Parkinson's Disease Patient
The rest is here:
Side Effects of Anti-Parkinson's Disease Medication In Abundance (Dyskinesis and Hallucinations) - Video
26-10-2011 02:31 Presented by Kelly Condefer, MD
Original post:
WVMC Doc Talks: Parkinson's Disease (Oct. 25, 2011) - Video
12-10-2011 04:21 Demonstration of early stage secondary Parkinson's disease symptoms (slurry speech, trouble initiating movements, loosing balance) on a 30 year old woman, who lost almost all of her putamen (part of the basal ganglia) on both sides of the brain resulting from the lack of oxygen in the injured part of her brain. The professional term for her injury is anoxic-ischemic brain injury. You can read up her story and make donations here: http://www.gofundme.com Join the free Facebook group I set up for her for following updates (www.facebook.com Date of Accident: June 7th, 2011. Video taken: Oct. 12th, 2011
Continued here:
Emese's (30) early stage secondary Parkinson's disease symtoms (anoxic-ischemic brain injury) - Video
23-09-2011 12:02 Mark Morris Dance Group performed in Ann Arbor Sept 23-24, 2011 as part of UMS's 11/12 Season. In this interview, David Leventhal discusses Dance for PD, an on-going collaboration between the Mark Morris Dance Group and the Brooklyn Parkinson Group.
View original post here:
Mark Morris Dance Group: Dance for Parkinson's Disease - Video
09-11-2011 14:00 Olga Momcilovic speaks at the 2011 CIRM Grantee Meeting about the use of induced pluripotent stem (iPS) cells to better understand the causes of Parkinson's and to develop therapies. Momcilovic is a CIRM Scholar and postdoctoral research fellow at the Buck Institute located in Novato, California.
More here:
Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video
31-10-2011 12:11 The Tango as Physical Therapy Parkinson's Disease. Performing at the Parkinson walk in Rome, GA for fundraising to increase PD awareness. Choreographer and Researcher, Madeleine Hackney Ph.D., Emory School of Medicine leads the performance with partner Ben Jackson, a Person with Parkinson's who was diagnosed at the age of 28. Clinical research studies continue to demonstrate physical benefits of the Argentine Tango for People with Parkinson's Disease. Parkinson's Disease is a chronic, progressive, neurodegenerative disorder of the central nervous system. PD symptoms are cognitive and non-motor as well as the more commonly recognized movement disorder symptoms. The CDC reports Parkinson's as the underlying cause of death for more than 20000 Americans every year. Currently, there is no treatment for Parkinson's Disease, and there is no cure. There is only treatment for certain symptoms of PD, all of which progress every day. See how you can help, Please visit gaparkinsons.org today!
Read the original here:
Parkinson's Disease and The Argentine Tango - Video
02-12-2011 11:39 Neurologist Dr. Michelle Brewer briefly defines Parkinson's disease. She also lists several symptoms that appear at the onset of this degenerative disorder. For more health information visit http://www.drbobshow.com.
Read the original:
Parkinson's Disease: What Are The Symptoms? - Video
11-11-2011 17:04
Continued here:
Marijuana (Hemp) Oil Fights Parkinson's Disease? - Video
09-11-2011 20:24 Andrew Feigin, MD, neurologist at Cushing Neuroscience Institute's Movement Disorders Center and Director of the Experimental Therapeutic at the Feinstein Institute for Medical Research explains the distinctions and brings us the latest information on current treatments and experimental therapies for Parkinson's disease and Huntington's disease. We meet a patient and his caregiver wife who both must cope with living with the under-publicized Huntington's disease everyday.
13-12-2011 22:03 This is another patient treated with Dr Omar Gonzalez method at Integra Medical Center
The rest is here:
Parkinson's disease patient at Integra Medical Center - Video